Carolyn Hendrickson, MD, MPH
|Title(s)||Assistant Professor, Medicine|
|School||School of Medicine|
|Address||1001 Potrero Ave|
San Francisco CA 94110
|University of California, San Francisco||Certificate||2014||Clinical Research|
|University of California, Berkeley||MPH||2008||Epidemiology|
|University of California, San Francisco||M.D.||2007|| Medicine|
|University of California, Santa Barbara||MA ||2003||Molecular, Cellular, Developmental Biology|
|University of California, Santa Barbara||BS||2001||Molecular, Cellular, Developmental Biology|
|University of California, Santa Barbara||BA||2001||English Literature|
|University of California, San Francisco, CA||06/2021||Diversity, Equity, and Inclusion Champion Training|
Dr. Hendrickson is a pulmonary and critical care medicine subspecialist with an expertise and research focus in acute lung injury and acute respiratory distress syndrome (ARDS), the most common life-threatening manifestation of COVID-19 disease. She is the medical director of the Medical Intensive Care Unit at Zuckerberg San Francisco General Hospital, the safety-net hospital for our county that has cared for approximately half of all ICU patients with COVID-19 disease in San Francisco. Dr. Hendrickson serves as the physician lead for the newly established COVID ICU.
COVID-19 Related Research Efforts:
As an ARDS translational researcher and the Medical Director of the Intensive Care Unit at Zuckerberg San Francisco General Hospital (ZSFG), Dr. Hendrickson pivoted her research endeavors to study COVID-19 disease with a specific interest in pneumonia and ARDS. She is the site principal investigator for two important COVID-19- related studies:
1. STAT Trial - a randomized clinical trial sponsored by the Department of Defense testing mesenchymal stromal cells for ARDS that primarily enrolls critically ill patients with ARDS
2. COMET Study- a longitudinal cohort study of hospitalized patients with COVID-19 disease with biospecimen collection sponsored by the National Institute of Health (https://www.comet-study.org). She is also the Clinical Operations Lead and a member of the Executive Committee for the COMET study.
Additionally, Dr. Hendrickson has leadership and site director roles in three other COVID-19-related randomized controlled clinical trials studying anticoagulation strategies, anti-inflammatory medications, and novel cell-based therapy for patients hospitalized with SARS-CoV-2 infection.